Takahashi T, Takeyoshi I, Hasegawa Y, Koyano T, Yamagishi T, Oshima K, Matsumoto K, Morishita Y
Second Department of Surgery, Gunma University School of Medicine, Japan.
J Heart Lung Transplant. 1999 Apr;18(4):285-91. doi: 10.1016/s1053-2498(98)00068-0.
Lazaroid, an inhibitor of iron-mediated lipid peroxidation, has been shown to reduce free radical-mediated injury after ischemia and reperfusion. The effect of Lazaroid U-74389G was investigated on ischemia-reperfusion injury of the heart through preservation and transplantation (Tx) in dogs.
Eleven pairs of adult mongrel dogs weighing 8.5 to 12 kg formed the recipient-donor combinations. Following electromechanical arrest of the heart using cardioplegia, the coronary vascular beds were washed out with a cold University of Wisconsin solution followed by 12-hour preservation and orthotopic Tx. Experimental animals were divided into 2 groups; 6 pairs formed the control group, and 5 formed the Lazaroid-treated group in which Lazaroid U-74389G at 10 mg/kg was administered intravenously 30 minutes before reperfusion of the heart. The cardiac function including cardiac output, left ventricular (LV) pressure, and LV dp/dt was assessed 2 hours after Tx by comparing it with the recovery rates (%) from cardiac function of donor dogs. Each transplanted heart was harvested for histological study.
The recovery of cardiac function after Tx was significantly better in the Lazaroid-treated group than in the control group. Histologically, myocardial damage, evaluated by both light and transmission electron microscopy, was less evident in the Lazaroid-treated group than in the control group.
Early cardiac function following Tx was significantly better and histological damage was less in the Lazaroid-treated group than in the control group, suggesting that Lazaroid U-74389G is effective in preventing ischemia-reperfusion injury after preservation and Tx.
拉扎罗类药物是一种铁介导的脂质过氧化抑制剂,已被证明可减轻缺血再灌注后自由基介导的损伤。通过犬心脏保存和移植,研究了拉扎罗类药物U-74389G对心脏缺血再灌注损伤的影响。
11对体重8.5至12千克的成年杂种犬组成受体-供体组合。使用心脏停搏液使心脏发生电机械性停搏后,用冷的威斯康星大学溶液冲洗冠状动脉血管床,随后进行12小时保存和原位移植。实验动物分为2组;6对组成对照组,5对组成拉扎罗类药物治疗组,在心脏再灌注前30分钟静脉注射10毫克/千克的拉扎罗类药物U-74389G。移植后2小时,通过与供体犬心脏功能的恢复率(%)进行比较,评估包括心输出量、左心室(LV)压力和LV dp/dt在内的心脏功能。摘取每个移植心脏进行组织学研究。
拉扎罗类药物治疗组移植后心脏功能的恢复明显优于对照组。在组织学上,通过光学显微镜和透射电子显微镜评估,拉扎罗类药物治疗组的心肌损伤比对照组轻。
拉扎罗类药物治疗组移植后的早期心脏功能明显优于对照组,组织学损伤也较轻,这表明拉扎罗类药物U-74389G在预防保存和移植后的缺血再灌注损伤方面有效。